Top 10 neurology clinical trial failure signals

Neurology trial failure analysis is difficult because stopped-trial language can mix scientific, operational, and strategic explanations. Some studies stop after weak efficacy, failed endpoints, or safety concerns. Others stop because recruitment is slow, endpoints change, or a sponsor reallocates resources.

This page uses the Clinical Trial Failures dataset to show the neurology interventions that appear most often in likely biological stopped-trial signals. The ranking is intentionally conservative: it is a discovery layer, not a final judgment about a molecule, mechanism, sponsor, or disease program.

The most useful workflow is to scan the top list, open the example NCT record, then move into the live database for related sponsors, phases, indications, and stop-reason language.

How to read this ranking

This ranking groups neurology stopped trials by the first listed intervention name. It captures repeated signals in the compact dataset, but it does not replace product-level due diligence or full registry review.

Efficacy/futility and safety buckets are treated as likely biological failure signals. Enrollment, funding, operational, strategic, regulatory, and unclear reasons are included in total stopped-trial counts but not in the biological-signal numerator.

Neurology has many heterogeneous conditions and endpoints. A stopped trial in dementia, epilepsy, pain, movement disorders, or neuropsychiatric disease can mean very different things. Use the table to prioritize which source records deserve review first.